Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Grand Pharmaceutical Group Limited has announced the approval and commercialization of its NOVASYNC Hybrid System for coronary artery imaging in China. This innovative system combines optical coherence tomography and intravascular ultrasound, enhancing coronary artery imaging and potentially reducing medical costs for patients with coronary heart disease. The development marks a significant milestone in the Group’s strategy to become a leader in cerebro-cardiovascular precision interventional diagnosis and treatment.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.